Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis | 19 | 2020 | 384 | 5.870 |
Why?
|
| Arthralgia | 6 | 2020 | 133 | 3.350 |
Why?
|
| Pain | 9 | 2020 | 426 | 2.520 |
Why?
|
| Osteoarthritis, Knee | 7 | 2020 | 400 | 2.250 |
Why?
|
| Arthritis, Experimental | 6 | 2020 | 132 | 2.020 |
Why?
|
| Nociceptors | 5 | 2019 | 27 | 1.980 |
Why?
|
| Hyperalgesia | 5 | 2017 | 52 | 1.850 |
Why?
|
| Ganglia, Spinal | 7 | 2020 | 68 | 1.730 |
Why?
|
| Animals | 31 | 2020 | 4722 | 1.560 |
Why?
|
| Neurons | 3 | 2017 | 378 | 1.350 |
Why?
|
| Immunity, Innate | 3 | 2020 | 97 | 1.340 |
Why?
|
| Disease Models, Animal | 16 | 2020 | 782 | 1.330 |
Why?
|
| Mice | 19 | 2020 | 1683 | 1.220 |
Why?
|
| Nerve Growth Factor | 2 | 2017 | 33 | 1.140 |
Why?
|
| Cartilage, Articular | 6 | 2018 | 550 | 1.070 |
Why?
|
| Chemokine CCL2 | 5 | 2018 | 24 | 1.030 |
Why?
|
| Neuroimmunomodulation | 3 | 2020 | 10 | 1.020 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2014 | 69 | 0.990 |
Why?
|
| Peptides | 3 | 2014 | 97 | 0.930 |
Why?
|
| Nociception | 4 | 2019 | 11 | 0.830 |
Why?
|
| Chronic Pain | 4 | 2020 | 111 | 0.790 |
Why?
|
| Tissue Engineering | 2 | 2011 | 39 | 0.740 |
Why?
|
| Receptors, CCR2 | 3 | 2017 | 10 | 0.700 |
Why?
|
| Synovitis | 1 | 2019 | 23 | 0.680 |
Why?
|
| Gene Expression | 2 | 2020 | 239 | 0.670 |
Why?
|
| Toll-Like Receptors | 1 | 2019 | 29 | 0.670 |
Why?
|
| Pain Management | 2 | 2018 | 144 | 0.670 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 86 | 0.660 |
Why?
|
| Calcium | 3 | 2018 | 502 | 0.650 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 271 | 0.650 |
Why?
|
| ADAM Proteins | 2 | 2015 | 66 | 0.620 |
Why?
|
| Aggrecans | 2 | 2018 | 157 | 0.610 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 34 | 0.600 |
Why?
|
| Cannabinoids | 1 | 2017 | 3 | 0.590 |
Why?
|
| Cannabis | 1 | 2017 | 6 | 0.590 |
Why?
|
| Phytotherapy | 1 | 2017 | 14 | 0.590 |
Why?
|
| Cytokines | 3 | 2019 | 351 | 0.590 |
Why?
|
| Knee Joint | 3 | 2019 | 826 | 0.580 |
Why?
|
| Clozapine | 1 | 2017 | 8 | 0.580 |
Why?
|
| Neural Inhibition | 1 | 2017 | 11 | 0.580 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 17 | 0.560 |
Why?
|
| Behavior, Animal | 1 | 2017 | 105 | 0.540 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 334 | 0.530 |
Why?
|
| Stifle | 1 | 2015 | 12 | 0.510 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 31 | 0.510 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 42 | 0.500 |
Why?
|
| Mice, Inbred C57BL | 8 | 2019 | 466 | 0.500 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2011 | 32 | 0.480 |
Why?
|
| Tissue Scaffolds | 2 | 2011 | 24 | 0.480 |
Why?
|
| Joints | 1 | 2014 | 99 | 0.450 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 14 | 0.440 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 13 | 0.440 |
Why?
|
| Menisci, Tibial | 4 | 2020 | 187 | 0.430 |
Why?
|
| Humans | 20 | 2020 | 30999 | 0.430 |
Why?
|
| Mice, Knockout | 5 | 2018 | 323 | 0.420 |
Why?
|
| Drug Carriers | 1 | 2011 | 8 | 0.390 |
Why?
|
| Blood Coagulation | 3 | 2006 | 20 | 0.390 |
Why?
|
| Heparin | 2 | 2010 | 25 | 0.390 |
Why?
|
| Orthopedic Procedures | 1 | 2014 | 329 | 0.370 |
Why?
|
| Chondroitin Sulfates | 1 | 2010 | 30 | 0.370 |
Why?
|
| Male | 12 | 2020 | 16447 | 0.360 |
Why?
|
| Chondrogenesis | 1 | 2010 | 31 | 0.360 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 35 | 0.350 |
Why?
|
| Plasma | 2 | 2006 | 34 | 0.320 |
Why?
|
| Cells, Cultured | 4 | 2015 | 686 | 0.310 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 78 | 0.290 |
Why?
|
| ADAMTS5 Protein | 2 | 2018 | 30 | 0.280 |
Why?
|
| Disease Progression | 2 | 2020 | 830 | 0.270 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 41 | 0.260 |
Why?
|
| RNA, Messenger | 2 | 2020 | 329 | 0.260 |
Why?
|
| Models, Theoretical | 3 | 2020 | 94 | 0.240 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 430 | 0.240 |
Why?
|
| Synovial Membrane | 2 | 2017 | 84 | 0.230 |
Why?
|
| Signal Transduction | 2 | 2019 | 498 | 0.230 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 330 | 0.230 |
Why?
|
| Hydrogels | 3 | 2014 | 9 | 0.220 |
Why?
|
| Cattle | 3 | 2014 | 219 | 0.210 |
Why?
|
| Analgesics | 2 | 2020 | 109 | 0.200 |
Why?
|
| Chondrocytes | 2 | 2014 | 208 | 0.190 |
Why?
|
| Bone Marrow Cells | 2 | 2011 | 59 | 0.190 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2020 | 8 | 0.180 |
Why?
|
| Radiography | 2 | 2014 | 695 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 261 | 0.180 |
Why?
|
| Microarray Analysis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 21 | 0.170 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2019 | 5 | 0.170 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2019 | 8 | 0.170 |
Why?
|
| Alarmins | 1 | 2019 | 2 | 0.170 |
Why?
|
| Nerve Growth Factors | 1 | 2020 | 49 | 0.170 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 165 | 0.160 |
Why?
|
| Biomarkers | 2 | 2019 | 733 | 0.160 |
Why?
|
| Phenotype | 1 | 2020 | 379 | 0.160 |
Why?
|
| ADAMTS4 Protein | 1 | 2018 | 19 | 0.150 |
Why?
|
| Matrix Metalloproteinases | 1 | 2018 | 23 | 0.150 |
Why?
|
| Ganglion Cysts | 1 | 2018 | 8 | 0.150 |
Why?
|
| Central Nervous System Sensitization | 1 | 2017 | 3 | 0.150 |
Why?
|
| Random Allocation | 2 | 2016 | 147 | 0.150 |
Why?
|
| TRPC Cation Channels | 1 | 2017 | 11 | 0.150 |
Why?
|
| Dronabinol | 1 | 2017 | 1 | 0.150 |
Why?
|
| Albuminuria | 1 | 2017 | 22 | 0.150 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 7 | 0.150 |
Why?
|
| Cannabidiol | 1 | 2017 | 4 | 0.150 |
Why?
|
| Rats | 2 | 2018 | 873 | 0.150 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2017 | 8 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 29 | 0.140 |
Why?
|
| Catalysis | 3 | 2013 | 13 | 0.140 |
Why?
|
| Chemokines, CC | 1 | 2017 | 8 | 0.140 |
Why?
|
| Patch-Clamp Techniques | 1 | 2017 | 116 | 0.140 |
Why?
|
| Female | 5 | 2020 | 16985 | 0.140 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 2 | 2014 | 5 | 0.140 |
Why?
|
| Osteonecrosis | 1 | 2017 | 19 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 34 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 468 | 0.140 |
Why?
|
| Chemokine CX3CL1 | 1 | 2016 | 3 | 0.140 |
Why?
|
| Drug Design | 2 | 2014 | 31 | 0.140 |
Why?
|
| Spinal Cord | 1 | 2017 | 107 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2017 | 125 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 115 | 0.130 |
Why?
|
| Calgranulin A | 1 | 2015 | 5 | 0.130 |
Why?
|
| alpha-Macroglobulins | 1 | 2015 | 13 | 0.130 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 736 | 0.130 |
Why?
|
| Adsorption | 2 | 2014 | 6 | 0.130 |
Why?
|
| Pain Measurement | 1 | 2018 | 489 | 0.130 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 8 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 16 | 0.130 |
Why?
|
| Microglia | 1 | 2016 | 132 | 0.130 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 3 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 33 | 0.120 |
Why?
|
| Horses | 1 | 2014 | 19 | 0.120 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2015 | 98 | 0.120 |
Why?
|
| Dogs | 1 | 2014 | 263 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2015 | 261 | 0.110 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 17 | 0.110 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 43 | 0.110 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 698 | 0.100 |
Why?
|
| Biotinylation | 1 | 2011 | 2 | 0.100 |
Why?
|
| Streptavidin | 1 | 2011 | 3 | 0.100 |
Why?
|
| Fluorometry | 1 | 2011 | 5 | 0.100 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 11 | 0.100 |
Why?
|
| Solubility | 1 | 2011 | 36 | 0.100 |
Why?
|
| Macrophages | 1 | 2012 | 137 | 0.100 |
Why?
|
| Glycosaminoglycans | 1 | 2011 | 53 | 0.100 |
Why?
|
| Protein Conformation | 1 | 2011 | 70 | 0.100 |
Why?
|
| DNA | 1 | 2011 | 124 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2011 | 37 | 0.100 |
Why?
|
| Kinetics | 1 | 2011 | 226 | 0.090 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 6 | 0.090 |
Why?
|
| Polysaccharide-Lyases | 1 | 2010 | 5 | 0.090 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2010 | 6 | 0.090 |
Why?
|
| Regeneration | 1 | 2010 | 27 | 0.090 |
Why?
|
| Models, Animal | 1 | 2010 | 130 | 0.090 |
Why?
|
| Injections, Intra-Articular | 1 | 2010 | 97 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2010 | 48 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2011 | 345 | 0.090 |
Why?
|
| Rabbits | 1 | 2010 | 286 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1311 | 0.080 |
Why?
|
| Surface Properties | 2 | 2006 | 133 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2008 | 7 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 60 | 0.070 |
Why?
|
| Arthroscopy | 1 | 2014 | 892 | 0.070 |
Why?
|
| Models, Biological | 2 | 2005 | 346 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 409 | 0.070 |
Why?
|
| Silanes | 1 | 2006 | 1 | 0.070 |
Why?
|
| Microscopy, Atomic Force | 1 | 2006 | 9 | 0.070 |
Why?
|
| Factor XII | 1 | 2005 | 1 | 0.060 |
Why?
|
| Prothrombin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Coagulants | 1 | 2005 | 9 | 0.060 |
Why?
|
| Biocompatible Materials | 1 | 2005 | 104 | 0.060 |
Why?
|
| Collagen Type V | 1 | 2020 | 4 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 583 | 0.040 |
Why?
|
| Skin | 1 | 2020 | 124 | 0.040 |
Why?
|
| Neurons, Afferent | 1 | 2018 | 7 | 0.040 |
Why?
|
| Sesquiterpenes, Guaiane | 1 | 2017 | 2 | 0.040 |
Why?
|
| Piperidines | 1 | 2017 | 33 | 0.040 |
Why?
|
| Indoles | 1 | 2017 | 50 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 133 | 0.040 |
Why?
|
| Podocytes | 1 | 2017 | 91 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2016 | 54 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 158 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 229 | 0.030 |
Why?
|
| Cricetinae | 1 | 2015 | 37 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 70 | 0.030 |
Why?
|
| Crystallization | 1 | 2014 | 5 | 0.030 |
Why?
|
| Epitopes | 1 | 2015 | 88 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 28 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 164 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 254 | 0.030 |
Why?
|
| Materials Testing | 1 | 2014 | 134 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2014 | 204 | 0.030 |
Why?
|
| Hypertension | 1 | 2015 | 288 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2008 | 11 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 31 | 0.020 |
Why?
|
| Binding Sites | 1 | 2008 | 75 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 124 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 1801 | 0.020 |
Why?
|
| Factor XIIa | 1 | 2005 | 1 | 0.020 |
Why?
|
| Titrimetry | 1 | 2005 | 3 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 12 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2005 | 51 | 0.020 |
Why?
|
| Thrombin | 1 | 2005 | 12 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 2005 | 19 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2005 | 135 | 0.010 |
Why?
|
| Adult | 1 | 2017 | 8933 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 10197 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 10047 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1672 | 0.010 |
Why?
|